Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.
Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, Revie J, Moore JD, Wiggins CM, Collinson RS, Mudd C, Tsonou E, Sadaie M, Bennett DC, Narita M, Torrance CJ, Keith WN. Cairney CJ, et al. Among authors: burns s. PLoS Genet. 2017 Aug 14;13(8):e1006942. doi: 10.1371/journal.pgen.1006942. eCollection 2017 Aug. PLoS Genet. 2017. PMID: 28806777 Free PMC article.
Dynamic telomerase gene suppression via network effects of GSK3 inhibition.
Bilsland AE, Hoare S, Stevenson K, Plumb J, Gomez-Roman N, Cairney C, Burns S, Lafferty-Whyte K, Roffey J, Hammonds T, Keith WN. Bilsland AE, et al. Among authors: burns s. PLoS One. 2009 Jul 31;4(7):e6459. doi: 10.1371/journal.pone.0006459. PLoS One. 2009. PMID: 19649288 Free PMC article.
Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma.
Lafferty-Whyte K, Bilsland A, Cairney CJ, Hanley L, Jamieson NB, Zaffaroni N, Oien KA, Burns S, Roffey J, Boyd SM, Keith WN. Lafferty-Whyte K, et al. Among authors: burns s. BMC Genomics. 2010 Oct 1;11:532. doi: 10.1186/1471-2164-11-532. BMC Genomics. 2010. PMID: 20920304 Free PMC article.
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD. Russell NH, et al. Among authors: burns s. J Clin Oncol. 2024 Nov 18:JCO2400259. doi: 10.1200/JCO.24.00259. Online ahead of print. J Clin Oncol. 2024. PMID: 39556780
1,585 results